Breakthroughs in hepatitis C research: from discovery to cure
MP Manns, B Maasoumy - Nature reviews Gastroenterology & …, 2022 - nature.com
In the 1970s, an unknown virus was suspected for documented cases of transfusion-
associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious …
associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious …
Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review
O Falade-Nwulia, C Suarez-Cuervo… - Annals of internal …, 2017 - acpjournals.org
Background: Rapid improvements in hepatitis C virus (HCV) therapy have led to the
approval of multiple oral direct-acting antiviral (DAA) regimens by the US Food and Drug …
approval of multiple oral direct-acting antiviral (DAA) regimens by the US Food and Drug …
EASL recommendations on treatment of hepatitis C 2016
European Association for The Study of The Liver - Journal of hepatology, 2017 - Elsevier
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy
M Reig, Z Mariño, C Perelló, M Iñarrairaegui… - Journal of …, 2016 - Elsevier
Background & Aims The success of direct-acting antivirals (DAA) against hepatitis C is a
major breakthrough in hepatology. Until now, however, there are very few data on the effect …
major breakthrough in hepatology. Until now, however, there are very few data on the effect …
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo …
C Villanueva, A Albillos, J Genescà, JC Garcia-Pagan… - The lancet, 2019 - thelancet.com
Background Clinical decompensation of cirrhosis is associated with poor prognosis.
Clinically significant portal hypertension (CSPH), defined by a hepatic venous pressure …
Clinically significant portal hypertension (CSPH), defined by a hepatic venous pressure …
[HTML][HTML] EASL recommendations on treatment of hepatitis C 2015
European Association For The Study Of The Liver - Journal of hepatology, 2015 - Elsevier
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …
EASL clinical practice guidelines: liver transplantation
European Association for The Study of the Liver - Journal of hepatology, 2016 - Elsevier
The first human orthotopic liver transplantation (LT) in Europe was performed by Sir Roy
Calne in Cambridge in 1968 [1], only one year after the first successful human liver …
Calne in Cambridge in 1968 [1], only one year after the first successful human liver …
[BOOK][B] WHO guidelines on hepatitis B and C testing
World Health Organization - 2017 - apps.who.int
Web Annexes Page 1 Page | i GUIDELINES ON HEPATITIS B AND C TESTING February 2017
GUIDELINES ANNEXES Page 2 Page | ii WHO guidelines on hepatitis B and C testing ISBN …
GUIDELINES ANNEXES Page 2 Page | ii WHO guidelines on hepatitis B and C testing ISBN …
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression
Background & Aims The risk of hepatocellular carcinoma (HCC) occurrence or recurrence
following direct-acting antiviral (DAA) hepatitis C virus (HCV) therapy remains unclear. The …
following direct-acting antiviral (DAA) hepatitis C virus (HCV) therapy remains unclear. The …
[PDF][PDF] Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
AASLD/IDSA HCV Guidance Panel, RT Chung… - …, 2015 - Wiley Online Library
The pace of hepatitis C virus (HCV) drug development in recent years has accelerated
dramatically. For patients to benefit from these impressive advances, practitioners need …
dramatically. For patients to benefit from these impressive advances, practitioners need …